P/B
7,5
Personalis
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
$1.8B
Market Cap • 9/25/2026
2011
(15 years)
Founded
2019
(7 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
25,2
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
2,4
EPS
—
Market Cap
Market Cap
1,8B
EV
1,6B
EV/Revenue
22,6
EV/EBITDA
-15,1
EV/EBIT
-13,8
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-8%
Total Yield
-8%
Payout
0%
Retained Earnings
-693M
Profitability
Gross Margin
12,7%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
80,5%
Capex/Revenue
12,5%
Capex/D&A
89,3%
Capex/OCF
-9,4%
SBC/OCF
—
% PPE
20,3%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
-3,3%
CAGR Op. Income 5Y
17,8%
CAGR Net Income 5Y
16,4%
CAGR EPS 5Y
-2,5%
CAGR OCF 5Y
10,4%
Leverage
N.D./EBITDA
1,7
Debt/Equity
0%
Current Ratio
5,3
Quick Ratio
4,9
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!